Drugs / PM534
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05835609 | Dec 2022 → Oct 2026 expected | — | PharmaMar | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-16 | PharmaMar | Results PharmaMar presents its scientific publications at the Annual Meeting of the American Association for Cancer Research (AACR) pharmamar.com ↗
PM534 is a novel tubulin-binding agent that exhibits a very high affinity for the colchicine-binding domain and overcomes the common resistance mechanisms that limit the efficacy of other tubulin-binding agents. |
| 2025-04-28 | PharmaMar | Results PharmaMar presents eleven scientific publications at the Annual Meeting of the American Association for Cancer Research (AACR) pharmamar.com ↗
PM534 is a novel tubulin-targeting agent, that may bypass the most common resistance mechanisms, limiting the effectiveness of standard microtubule-binding drugs. |
| 2023-04-17 | PharmaMar | Results PharmaMar to present new data on its compounds at AACR 2023 Congress pharmamar.com ↗
The first of the abstracts, entitled “PM534 is a novel microtubule-destabilizing agent with high affinity and potent antineoplastic properties“, demonstrates by X-ray crystallography that PM534 binds to its target, tubulin, inducing a strong antitumor effect in vitro and in vivo. |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM534 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05835609 ↗ |
| Route | Intravenous | “All Patients will receive PM534 via intravenous.” NCT05835609 ↗ |